# The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy

> **NCT02910297** · — · WITHDRAWN · sponsor: **Gillette Children's Specialty Healthcare**

## Conditions studied

- Dravet Syndrome
- Lennox Gastaut Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02910297
- **Lead sponsor:** Gillette Children's Specialty Healthcare
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** unable to recruit enough subjects on CBD
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910297, "The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02910297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*